Zevra Therapeutics Forecast, price target & analysts
Zevra Therapeutics Target price 2026 - Analyst rating & recommendation
Zevra Therapeutics Classifications & Recommendation
Zevra Therapeutics Price Target
| Target Price | $24.99 |
| Price | $10.97 |
| Potential |
127.80%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Zevra Therapeutics 2027 .
The average Zevra Therapeutics target price is $24.99.
This is
127.80%
register free of charge
$36.75
235.00%
register free of charge
$20.20
84.14%
register free of charge
|
|
| A rating was issued by 15 analysts: 14 Analysts recommend Zevra Therapeutics to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Zevra Therapeutics stock has an average upside potential 2027 of
127.80%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 106.47 | 155.26 |
| 350.95% | 45.83% | |
| EBITDA Margin | -0.17% | 62.15% |
| 99.95% | 36,861.73% | |
| Net Margin | 72.87% | 41.58% |
| 116.31% | 42.94% |
11 Analysts have issued a sales forecast Zevra Therapeutics 2026 . The average Zevra Therapeutics sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Zevra Therapeutics EBITDA forecast 2026. The average Zevra Therapeutics EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Zevra Therapeutics Analysts have issued a net profit forecast 2026. The average Zevra Therapeutics net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 1.35 | 1.09 |
| 159.21% | 19.26% | |
| P/E | 10.42 | |
| EV/Sales | 2.82 |
11 Analysts have issued a Zevra Therapeutics forecast for earnings per share. The average Zevra Therapeutics EPS is
This results in the following potential growth metrics and future valuations:
Zevra Therapeutics...
Current Zevra Therapeutics Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 20 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| Citizens |
Locked
➜
Locked
|
Locked | Aug 06 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Jul 27 2026 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Jul 27 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Jul 27 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 23 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 20 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
Citizens:
Locked
➜
Locked
|
Aug 06 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Jul 27 2026 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Jul 27 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Jul 27 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 23 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
